ACADIA Pharm

ACAD NASDAQ
25.65
-0.05
-0.19%
Opening 10:27 07/22 EDT
Open
25.60
Prev Close
25.70
High
26.04
Low
25.60
Volume
115.53K
Avg Vol (3M)
989.57K
52 Week High
28.67
52 Week Low
12.77
% Turnover
0.08%
Market Cap
3.70B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ACADIA Pharm ACAD stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
MORE >

Recently

Name
Price
%Change